We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Circio Holding Asa | LSE:0RIS | London | Ordinary Share | NO0013033795 | CIRCIO HOLDING ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 15.98 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Home Health Care Services | 10M | -432.9M | -2.2969 | -6.96 | 3.01B |
OSLO, Norway, Nov. 11, 2019 /PRNewswire/ -- Targovax ASA (OSE: TRVX), announces that clinical data from its combination trial with ONCOS-102 and Keytruda in anti-PD1 refractory melanoma was presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Dr. Shoushtari, MD, Medical Oncologist, Memorial Sloan Kettering, presented results from part 1 of Targovax's phase I trial in anti-PD1 refractory melanoma combining ONCOS-102 with Keytruda. Headline data were released in July, showing that three out of nine patients had significant reduction of tumor burden (33% overall response rate, ORR), including one patient with a complete response, which is rarely seen in this late-stage patient population Please see the full presentation here: SITC presentation
Øystein Soug, CEO of Targovax, commented: "Although the number of patients is small, 33% ORR is very encouraging and confirms our hypothesis that ONCOS-102 can immune activate PD-1 refractory tumors to respond to re-challenge with Keytruda. We are very excited that these data are being recognized with an oral presentation at the SITC Annual Meeting."
Part 2 of the trial is currently enrolling patients, where an extended ONCOS-102 dosing regimen is being assessed.
An extended presentation will be given by Dr. Shoushtari at an investor event in NYC later this week:
SOLEBURY TROUT KOL DAY
Date: | 15 November 2019 |
Time and place | 2 pm ET; NYC, US |
Presenter: | Dr. Alexander Shoushtari, Principal Investigator, Memorial Sloan Kettering Cancer Center, NYC |
Webcast: | https://services.choruscall.com/links/trvx191115.html |
For more information about the Solebury Trout KOL day or to RSVP, institutional investors and sell-side analysts may contact access@troutgroup.com.
KOL biography:
Alexander N. Shoushtari, MD, Medical Oncologist, Memorial Sloan Kettering
Dr. Shoushtari is a renowned expert in melanoma, with a research focus on uveal and mucosal melanomas. He has been part of several immunotherapy trials at MSKCC and is the Principal Investigator on the ONCOS-102 phase I trial in CPI refractory advanced melanoma. Dr. Shoushtari is a member of the research team of Dr. Jedd Wolchok, MD, PhD, Chief, Melanoma and Immunotherapeutics Service at the Memorial Sloan Kettering Cancer Center.
For further information, please contact:
Renate Birkeli
Investor Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/targovax/r/presentation-of-oncos-102-melanoma-data-at-sitc-annual-meeting,c2958264
The following files are available for download:
https://mb.cision.com/Public/17093/2958264/920422e203543ab4.pdf | SITC presentation |
View original content:http://www.prnewswire.com/news-releases/presentation-of-oncos-102-melanoma-data-at-sitc-annual-meeting-300955285.html
SOURCE Targovax
Copyright 2019 PR Newswire
1 Year Circio Holding Asa Chart |
1 Month Circio Holding Asa Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions